CD5 and diffuse large B-cell lymphoma: As only two cases of SN‐DLBCL with available tissue samples could be analyzed for the expression of MYC, BCL2, p53, and CD5, the enrollment of more patients with SN‐DLBCL, including I to IV, to further assess whether these molecules can serve as prognostic markers in patients with SN‐DLBCL is needed.